The role of tumour markers in ovarian cancer

G. Gargano, M. Correale, I. Abbate, G. Falco, N. De Frenza, V. Lo russo, M. De Lena, A. De Leonardis

Research output: Contribution to journalArticlepeer-review


In the present review, the Authors have evaluated the current status of the utilization of the principle tumor markers for ovarian carcinoma in clinical gynecological practice. The major difficulty in individualizing a single marker is represented by the histological differentiation of the tumor itself. In fact, whereas for the malignant germ cell tumors, useful markers (AFP, B-HCG) are already available, for other histological forms, valid markers have been identified only because of the availability of the monoclonal antibody: CA 125. Even if this marker cannot be proposed for mass screening, it represents a useful instrument for the diagnosis and monitoring of ovarian carcinoma. The serum levels are well correlated with the clinical status of the patient and high concentrations of the marker are strongly indicative of disease progression at the second-look. Numerous other markers such as NB 70K, IAP, PLAP, CA 15-3 and TAG 72, are actually in the clinical evaluation phase, for the most part in association with CA 125.

Original languageEnglish
Pages (from-to)23-29
Number of pages7
JournalClinical and Experimental Obstetrics and Gynecology
Issue number1
Publication statusPublished - 1990

ASJC Scopus subject areas

  • Obstetrics and Gynaecology


Dive into the research topics of 'The role of tumour markers in ovarian cancer'. Together they form a unique fingerprint.

Cite this